Bimagrumab: adverse events and evidence limits
A 48-week intravenous bimagrumab trial in type 2 diabetes with overweight or obesity reported diarrhea and muscle spasms. Serious events occurred in both arms; pancreatitis occurred in the bimagrumab arm. [1]
Occurrence does not establish causation. This cohort and preparation do not establish another product’s risks. [1]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Diarrhea | Adults with type 2 diabetes and overweight or obesity, intravenous, 48 weeks | Reported; no frequency given | [1] |
| Muscle spasms | The same participants | Reported; no frequency given | [1] |
| Pancreatitis (serious event) | The bimagrumab arm of the same trial | Occurred in the bimagrumab arm; serious events occurred in both arms; occurrence does not establish causation | [1] |
References
- Steven B Heymsfield et al. (2021). Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial https://doi.org/10.1001/jamanetworkopen.2020.33457.